Walter M. Stadler to Immunotherapy
This is a "connection" page, showing publications Walter M. Stadler has written about Immunotherapy.
Connection Strength
0.482
-
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 12; 20(6):510-514.
Score: 0.139
-
Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000 Mar 15; 88(6):1317-24.
Score: 0.119
-
Renal cancer immunotherapy: a ray of hope or regression to the mean? Cancer Invest. 2000; 18(5):490-1.
Score: 0.117
-
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2022 02; 20(1):1-10.
Score: 0.033
-
Kidney cancer. Lancet. 1998 Nov 21; 352(9141):1691-6.
Score: 0.027
-
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget. 2016 10 18; 7(42):69014-69023.
Score: 0.023
-
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009 Aug; 27(4):379-86.
Score: 0.013
-
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
Score: 0.010